Cancer Institute A national cancer institute
designated cancer center
Profile http://med.stanford.edu/profiles/cancer/researcher/Peter_Sarnow/
Email this profile
Portrait View Larger

Peter Sarnow

Academic Appointments

  • Professor of Microbiology and Immunology

Key Documents

Contact Information

  • Academic Offices
    Personal Information
    Email Tel (650) 498-7074 Tel (650) 498-7076

Bio

Academic Appointments

Administrative Appointments

  • Chair, Dept. of Microbiology & Immunology, Stanford University School of Medicine (2010 - present)
  • Member of School of Medicine Awards Committee, Stanford University School of Medicine (2005 - present)
  • Member of the Committee on Graduate Studies, Stanford University (2001 - 2004)
  • Director of Graduate Program, Dept. Microbiology and Immunology, Stanford University School of Medicine (2002 - present)

Honors and Awards

  • Fellow, American Association for the Advancement of Science (2010)
  • Editor, Virology (2003-present)
  • The Sidney and Skippy Frank Prize, Institute for Immunity, Transplantation and Infection, Stanford University (2006)
  • Faculty Research Award, American Cancer Society (1992-1997)
  • Postdoctoral Fellowship, Deutsche Forschungsgemeinschaft (1982-1985)
  • Predoctoral Fellowship, Studienstiftung des Deutschen Volkes (1979-1982)

Professional Education

Ph.D.: SUNY at Stony Brook, Molecular Virology (1982)
B.S.: University of Konstanz, Molecular Genetics (1979)

Research & Scholarship

Current Research and Scholarly Interests

Our laboratory has been been studying the mechanism by which a liver-specific microRNA, miR-122, regulates the amplification of the hepatitis C virus (HCV) genome in cultured cells. Specifically, we have found that miR-122 interacts with the 5' end of the viral RNA and is essential for viral replication. Consequently, sequestration of miR-122 by antisense-oligonucleotides results in rapid loss of viral RNA. We are currently examining the mechanism by which miR-122 helps HCV RNA replication and are searching for cellular targets of miR-122 and their regulation by miR-122. These lines of investigations will lead to new insights how these small noncoding RNAs regulate expression of cellular and viral mRNAs and may point to new venues for antiviral therapeutics against HCV.

In a second line of investigation, we are studying the unusual mechanism of translation initiation by internal ribosome entry in certain viral (i.e. HCV, picornavirsues and some insect viruses) and cellular mRNA molecules. In the conventional scanning mechanism of translation initiation, which operates on most mRNA molecules, 40S subunits are recruited at or near the 5' end of the mRNA. Subsequently, the 40S ribosomal subunits are predicted to scan the mRNA in a 5' to 3' direction until the first AUG codon is encountered as start site for protein synthesis. However, certain viral and cellular mRNAs, notably encoding proto-oncogenes and regulatory genes, contain long 5' noncoding regions with multiple AUG codons. Thus, the translation initiation rate in these mRNAs is predicted to be low according to the scanning model; alternatively, other translation initiation mechanisms may operate to ensure efficient translation. Indeed, some of such mRNAs with long leaders contain internal ribosome entry sites which can bind ribosomes directly. Much of our work has been focussing on the mechanism and prevalence of internal ribosome binding. Specifically, we are addressing the following questions: Which cellular and viral mRNAs can be translated by internal ribosome binding? What are the cellular gene products that mediate internal ribosome binding? Is internal initiation regulated in the cell? What is the molecular basis for designating a given AUG codon as start site codon?

Teaching

Courses

2013-14

Graduate and Fellowship Program Affiliations

Publications

Publications

Publication tag cloud

Publication Topics

View All 106

Stanford Medicine Resources:

Footer Links: